NEUROCRINE BIOSCIENCES INC
NBIX evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $15.98B
- Lead Asset:
- crinecerfont (Phase 3)
What it means
What to watch
Prepared research question
What matters most for NBIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NBIX
Neurocrine Biosciences Inc. (NBIX) is a neuroscience-focused biopharmaceutical company with approved products Ingrezza and Crenessity, a deep pipeline in neuropsychiatry, and a strong cash position as of mid-2026.
Key risk: Ingrezza price risk 2029
BioSniper Score
Based on 5 of 6 signals
Market Cap
$15.98B
Cash Runway
—
Lead Asset
crinecerfont (Phase 3)Next Catalyst
Phase2_Start · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 39 clinical trials · 3 catalysts · 4 FDA decisions for NEUROCRINE BIOSCIENCES INC.
Neurocrine Biosciences Inc. (NBIX) is a neuroscience-focused biopharmaceutical company with approved products Ingrezza and Crenessity, a deep pipeline in neuropsychiatry, and a strong cash position as of mid-2026.
- Cash & equivalents of $332.4M as of 2026-06-30 [sec].
- Total revenue of $959.0M and net income of $144.4M as of 2026-06-30 [sec].
- Approved products include Ingrezza (valbenazine) for tardive dyskinesia and Huntington's chorea, and Crenessity (crinecerfont) for congenital adrenal hyperplasia [news].
- Phase 2 trial launched for next-generation VMAT2 inhibitor NBI-1065890 in tardive dyskinesia [news].
- Crinecerfont is in Phase 3 for congenital adrenal hyperplasia with Orphan Drug and Breakthrough Therapy designations [pipeline].
What works
- Strong commercial product portfolio with Ingrezza and Crenessity driving revenue growth [news].
- Deep pipeline with multiple mid- and late-stage programs, including crinecerfont and NBI-1065890 [pipeline][news].
- Substantial cash position of $332.4M as of 2026-06-30 provides financial flexibility [sec].
- Orphan Drug and Breakthrough Therapy designations for crinecerfont may accelerate development and market access [pipeline].
What to weigh
- Ingrezza faces a potential price hit in 2029, creating revenue concentration risk [news].
- Luvadaxistat failed to show significant improvement in a Phase 2 schizophrenia trial [catalyst].
- Crinecerfont's market faces competition from over two dozen steroid-based products and other clinical programs [pipeline].
- Share price showed a 9.23% decline over one year as of early 2026 [news].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2026-12-01 · Phase2_Start: NBIP-01435 in Classic Congenital Adrenal Hyperplasia — A Phase 2 open-label study to evaluate efficacy, safety, tolerability, and pharmacokinetics in adults.
- 2040-08-10 · Patent_Expiry: VALBENAZINE TOSYLATE — Patent expiry for NDA209241, which may affect market exclusivity.
- 2041-06-09 · Patent_Expiry: CRINECERFONT — Patent expiry for NDA218808, which may affect market exclusivity.
Risks & what to watch (4)›
Key risks
- Ingrezza price risk 2029 — Ingrezza faces a potential price reduction in 2029, which could impact revenue [news].
- Luvadaxistat trial failure — Phase 2 trial of luvadaxistat did not significantly improve cognitive scores versus placebo [catalyst].
- Crinecerfont competitive landscape — Crinecerfont competes with over two dozen steroid products and other CAH programs [pipeline].
- Share price decline — One-year total shareholder return was a 9.23% decline as of early 2026 [news].
What to watch
- Phase 2 trial of NBI-1065890 in tardive dyskinesia, with primary endpoint at Week 8 [news].
- Phase 2 pediatric study of crinecerfont in CAH starting 2026-07-01 [catalyst].
- Data-rich 2027 with multiple mid- and late-stage readouts expected [news].
- Ingrezza's commercial performance and potential 2029 pricing impact [news].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run NEUROCRINE BIOSCIENCES INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NEUROCRINE BIOSCIENCES INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.45 · 3% dilution
Lead: Approved
2 candidates
3 upcoming, next in ~48d
0 buys · 27 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 7.8%
- Days to cover
- 5.1
- Shares short
- 5,992,527
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NBIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for NEUROCRINE BIOSCIENCES INC?
Neurocrine Biosciences Inc. (NBIX) is a neuroscience-focused biopharmaceutical company with approved products Ingrezza and Crenessity, a deep pipeline in neuropsychiatry, and a strong cash position as of mid-2026.
What is NEUROCRINE BIOSCIENCES INC's lead drug candidate?
NEUROCRINE BIOSCIENCES INC's most advanced tracked candidate is crinecerfont (Phase 3) for Congenital Adrenal Hyperplasia.
What is NEUROCRINE BIOSCIENCES INC's next catalyst?
NEUROCRINE BIOSCIENCES INC's next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia" — expected December 1, 2026.
Who is the CEO of NEUROCRINE BIOSCIENCES INC?
Mr. Kyle W. Gano Ph.D. is the chief executive officer of NEUROCRINE BIOSCIENCES INC (NBIX).
Where is NEUROCRINE BIOSCIENCES INC headquartered?
NEUROCRINE BIOSCIENCES INC (NBIX) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.